F10 and Stroke: The current US and European guidelines recommend FXa inhibitors and direct thrombin inhibitor over warfarin for stroke prevention in high-risk patients with atrial fibrillation.13,14 FXa inhibitors do not require therapeutic monitoring and are associated with fewer adverse effects and lower rates of bleeding complications, particularly hemorrhagic stroke, than warfarin.